BIOCRYST PHARMACEUTICALS INC (BCRX) — insider trading
Health Care · NASDAQ
BIOCRYST PHARMACEUTICALS INC (BCRX) has 34 reported SEC Form 4 insider transactions in our data, including 2 open-market sales among the most recent 34 (latest 2026-08-31).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | Stonehouse Jon P | Director | Grant / award / vesting | 644 | $9.70 | $6.2K | Form 4 |
| 2026-08-31 | Milne Jill C. | Director | Grant / award / vesting | 1,288 | $9.70 | $12.5K | Form 4 |
| 2026-08-31 | MILANO VINCENT | Director | Grant / award / vesting | 1,159 | $9.70 | $11.2K | Form 4 |
| 2026-08-31 | McKee Amy E | Director | Grant / award / vesting | 644 | $9.70 | $6.2K | Form 4 |
| 2026-08-31 | Frank Steven | Director | Grant / award / vesting | 1,288 | $9.70 | $12.5K | Form 4 |
| 2026-06-11 | HEGGIE THERESA | Director | Grant / award / vesting (derivative) | 33,540 | — | $0 | Form 4 |
| 2026-06-11 | HEGGIE THERESA | Director | Grant / award / vesting | 15,294 | — | $0 | Form 4 |
| 2026-06-11 | McKee Amy E | Director | Grant / award / vesting (derivative) | 33,540 | — | $0 | Form 4 |
| 2026-06-11 | McKee Amy E | Director | Grant / award / vesting | 15,294 | — | $0 | Form 4 |
| 2026-06-11 | Stonehouse Jon P | Director | Grant / award / vesting (derivative) | 33,540 | — | $0 | Form 4 |
| 2026-06-11 | Stonehouse Jon P | Director | Grant / award / vesting | 15,294 | — | $0 | Form 4 |
| 2026-06-11 | MILANO VINCENT | Director | Grant / award / vesting (derivative) | 33,540 | — | $0 | Form 4 |
| 2026-06-11 | MILANO VINCENT | Director | Grant / award / vesting | 15,294 | — | $0 | Form 4 |
| 2026-06-11 | SANDERS MACHELLE | Director | Grant / award / vesting (derivative) | 33,540 | — | $0 | Form 4 |
| 2026-06-11 | SANDERS MACHELLE | Director | Grant / award / vesting | 15,294 | — | $0 | Form 4 |
| 2026-06-11 | Frank Steven | Director | Grant / award / vesting (derivative) | 33,540 | — | $0 | Form 4 |
| 2026-06-11 | Frank Steven | Director | Grant / award / vesting | 15,294 | — | $0 | Form 4 |
| 2026-06-11 | LEVIN ALAN G | Director | Grant / award / vesting (derivative) | 33,540 | — | $0 | Form 4 |
| 2026-06-11 | LEVIN ALAN G | Director | Grant / award / vesting | 15,294 | — | $0 | Form 4 |
| 2026-06-11 | Galson Steven K | Director | Grant / award / vesting (derivative) | 33,540 | — | $0 | Form 4 |
| 2026-06-11 | Galson Steven K | Director | Grant / award / vesting | 15,294 | — | $0 | Form 4 |
| 2026-06-11 | Milne Jill C. | Director | Grant / award / vesting (derivative) | 33,540 | — | $0 | Form 4 |
| 2026-06-11 | Milne Jill C. | Director | Grant / award / vesting | 15,294 | — | $0 | Form 4 |
| 2026-05-29 | Frank Steven | Director | Grant / award / vesting | 1,262 | $8.91 | $11.2K | Form 4 |
| 2026-05-29 | MILANO VINCENT | Director | Grant / award / vesting | 1,122 | $8.91 | $10.0K | Form 4 |
| 2026-05-29 | McKee Amy E | Director | Grant / award / vesting | 631 | $8.91 | $5.6K | Form 4 |
| 2026-05-29 | Stonehouse Jon P | Director | Grant / award / vesting | 631 | $8.91 | $5.6K | Form 4 |
| 2026-05-29 | Milne Jill C. | Director | Grant / award / vesting | 1,262 | $8.91 | $11.2K | Form 4 |
| 2026-05-18 | McKee Amy E | Director | Open-market sale | 11,180 | $8.97 | $100.3K | Form 4 |
| 2026-05-13 | Barnes Alane P | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 62,500 | — | $0 | Form 4 |
| 2026-05-13 | Barnes Alane P | Officer (Chief Legal Officer) | Open-market sale | 62,500 | $9.54 | $596.3K | Form 4 |
| 2026-05-13 | Barnes Alane P | Officer (Chief Legal Officer) | Option exercise / conversion | 62,500 | $5.04 | $315.0K | Form 4 |
| 2026-04-06 | Menon Sandeep | Officer (Chief R&D Officer) | Grant / award / vesting (derivative) | 441,350 | — | $0 | Form 4 |
| 2026-04-06 | Menon Sandeep | Officer (Chief R&D Officer) | Grant / award / vesting | 205,150 | — | $0 | Form 4 |
Ask the chat about BCRX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: BIOCRYST PHARMACEUTICALS INC (BCRX).
Last updated 2026-08-31 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.